Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2026
Medically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards Update.
Journal: JCO oncology practice
Published: May 27, 2025
Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Journal: JCO clinical cancer informatics
Published: March 05, 2025
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Journal: JCO clinical cancer informatics
Published: December 20, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: April 17, 2024
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma.
Journal: Frontiers in oncology
Published: April 21, 2023
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: August 18, 2021
Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR).
Journal: ClinicoEconomics and outcomes research : CEOR
Published: May 28, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Journal: Clinical genitourinary cancer
Published: January 17, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026